Concepts (121)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 5 | 2024 | 37 | 3.380 |
Why?
|
| Coronary Artery Disease | 5 | 2023 | 30 | 2.420 |
Why?
|
| Cardiomyopathy, Dilated | 3 | 2023 | 35 | 1.830 |
Why?
|
| Percutaneous Coronary Intervention | 4 | 2023 | 12 | 1.720 |
Why?
|
| Myocardial Infarction | 3 | 2023 | 24 | 1.560 |
Why?
|
| Cardiac Surgical Procedures | 3 | 2021 | 6 | 1.170 |
Why?
|
| Comorbidity | 3 | 2024 | 184 | 1.120 |
Why?
|
| ST Elevation Myocardial Infarction | 2 | 2023 | 4 | 1.040 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2023 | 46 | 0.980 |
Why?
|
| Heart Diseases | 3 | 2024 | 19 | 0.950 |
Why?
|
| Metabolome | 1 | 2024 | 2 | 0.930 |
Why?
|
| Humans | 24 | 2024 | 14077 | 0.900 |
Why?
|
| Aging | 1 | 2024 | 109 | 0.870 |
Why?
|
| Atrial Fibrillation | 1 | 2023 | 4 | 0.860 |
Why?
|
| Vascular Diseases | 1 | 2023 | 5 | 0.850 |
Why?
|
| Cannabis | 1 | 2023 | 10 | 0.850 |
Why?
|
| Coronary Artery Bypass | 2 | 2021 | 4 | 0.790 |
Why?
|
| Neuroprotection | 1 | 2021 | 4 | 0.790 |
Why?
|
| Risk Factors | 9 | 2023 | 1431 | 0.780 |
Why?
|
| Intraoperative Complications | 2 | 2021 | 8 | 0.740 |
Why?
|
| HIV | 3 | 2018 | 380 | 0.720 |
Why?
|
| Hemorrhage | 1 | 2021 | 70 | 0.700 |
Why?
|
| Patient Care Management | 1 | 2019 | 9 | 0.650 |
Why?
|
| Ambulatory Care | 1 | 2019 | 54 | 0.630 |
Why?
|
| Stroke Volume | 3 | 2023 | 42 | 0.610 |
Why?
|
| HIV Infections | 6 | 2024 | 4946 | 0.600 |
Why?
|
| Emergencies | 1 | 2018 | 16 | 0.600 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2019 | 247 | 0.550 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 29 | 0.550 |
Why?
|
| Registries | 1 | 2016 | 89 | 0.530 |
Why?
|
| Male | 9 | 2024 | 6489 | 0.440 |
Why?
|
| Ventricular Function, Left | 3 | 2023 | 80 | 0.420 |
Why?
|
| Prospective Studies | 6 | 2023 | 1131 | 0.410 |
Why?
|
| Middle Aged | 7 | 2023 | 3425 | 0.400 |
Why?
|
| Acute Kidney Injury | 2 | 2021 | 15 | 0.380 |
Why?
|
| Adult | 6 | 2023 | 5664 | 0.360 |
Why?
|
| Aged | 4 | 2024 | 1650 | 0.360 |
Why?
|
| Coronary Vessels | 2 | 2023 | 12 | 0.330 |
Why?
|
| Hypertension | 2 | 2024 | 397 | 0.330 |
Why?
|
| South Africa | 7 | 2023 | 7312 | 0.300 |
Why?
|
| Coronary Stenosis | 2 | 2019 | 4 | 0.290 |
Why?
|
| Antihypertensive Agents | 2 | 2024 | 61 | 0.280 |
Why?
|
| Female | 7 | 2023 | 8751 | 0.280 |
Why?
|
| Genetic Testing | 2 | 2023 | 33 | 0.250 |
Why?
|
| Predictive Value of Tests | 2 | 2023 | 183 | 0.250 |
Why?
|
| Prognosis | 2 | 2023 | 197 | 0.250 |
Why?
|
| Coronary Angiography | 2 | 2023 | 14 | 0.240 |
Why?
|
| Treatment Outcome | 3 | 2023 | 867 | 0.240 |
Why?
|
| Metabolomics | 1 | 2024 | 5 | 0.230 |
Why?
|
| Postoperative Complications | 2 | 2021 | 32 | 0.230 |
Why?
|
| Kidney Diseases | 1 | 2024 | 38 | 0.230 |
Why?
|
| Losartan | 1 | 2023 | 2 | 0.220 |
Why?
|
| Cardiovascular Agents | 2 | 2020 | 11 | 0.220 |
Why?
|
| Uric Acid | 1 | 2023 | 6 | 0.220 |
Why?
|
| Gadolinium | 1 | 2023 | 5 | 0.220 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2023 | 5 | 0.220 |
Why?
|
| Contrast Media | 1 | 2023 | 6 | 0.220 |
Why?
|
| Risk Assessment | 1 | 2024 | 217 | 0.220 |
Why?
|
| Research Design | 1 | 2024 | 123 | 0.220 |
Why?
|
| Perioperative Care | 1 | 2021 | 8 | 0.190 |
Why?
|
| Ultrasonography, Doppler | 1 | 2021 | 6 | 0.190 |
Why?
|
| Morbidity | 1 | 2021 | 37 | 0.190 |
Why?
|
| Kidney | 1 | 2021 | 46 | 0.190 |
Why?
|
| Retrospective Studies | 2 | 2021 | 767 | 0.190 |
Why?
|
| Sternum | 1 | 2021 | 1 | 0.190 |
Why?
|
| Operative Time | 1 | 2021 | 4 | 0.190 |
Why?
|
| Surgical Wound Infection | 1 | 2021 | 13 | 0.180 |
Why?
|
| Respiration, Artificial | 1 | 2021 | 46 | 0.180 |
Why?
|
| Hospital Mortality | 1 | 2021 | 94 | 0.180 |
Why?
|
| Smoking | 1 | 2021 | 99 | 0.170 |
Why?
|
| Age Factors | 1 | 2021 | 364 | 0.170 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2019 | 11 | 0.170 |
Why?
|
| Family Health | 1 | 2019 | 16 | 0.170 |
Why?
|
| Ultrasonography, Interventional | 1 | 2019 | 10 | 0.160 |
Why?
|
| Work Simplification | 1 | 2019 | 1 | 0.160 |
Why?
|
| Evidence-Based Practice | 1 | 2019 | 4 | 0.160 |
Why?
|
| Acute Coronary Syndrome | 1 | 2019 | 13 | 0.160 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2019 | 27 | 0.160 |
Why?
|
| Echocardiography | 1 | 2019 | 99 | 0.160 |
Why?
|
| Asia | 1 | 2019 | 70 | 0.160 |
Why?
|
| Ventricular Remodeling | 1 | 2019 | 44 | 0.160 |
Why?
|
| Quality Improvement | 1 | 2019 | 32 | 0.160 |
Why?
|
| Follow-Up Studies | 2 | 2016 | 367 | 0.150 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 123 | 0.150 |
Why?
|
| Incidence | 2 | 2017 | 655 | 0.150 |
Why?
|
| Africa | 1 | 2019 | 360 | 0.150 |
Why?
|
| Mass Screening | 1 | 2019 | 242 | 0.140 |
Why?
|
| Myocardial Ischemia | 1 | 2017 | 12 | 0.140 |
Why?
|
| Time Factors | 1 | 2016 | 503 | 0.120 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2014 | 2 | 0.120 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2014 | 3 | 0.120 |
Why?
|
| Drug-Eluting Stents | 1 | 2014 | 3 | 0.120 |
Why?
|
| Blood Pressure | 2 | 2024 | 312 | 0.090 |
Why?
|
| Chronic Disease | 2 | 2020 | 100 | 0.080 |
Why?
|
| Electrocardiography | 2 | 2019 | 35 | 0.070 |
Why?
|
| Global Health | 2 | 2017 | 183 | 0.060 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2024 | 9 | 0.060 |
Why?
|
| Enalapril | 1 | 2023 | 6 | 0.060 |
Why?
|
| Perindopril | 1 | 2023 | 4 | 0.060 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2023 | 28 | 0.060 |
Why?
|
| Prevalence | 2 | 2017 | 1149 | 0.050 |
Why?
|
| Young Adult | 2 | 2019 | 2357 | 0.050 |
Why?
|
| Portal Vein | 1 | 2021 | 2 | 0.050 |
Why?
|
| Renal Circulation | 1 | 2021 | 5 | 0.050 |
Why?
|
| Hepatic Veins | 1 | 2021 | 2 | 0.050 |
Why?
|
| Coronary Restenosis | 1 | 2021 | 4 | 0.050 |
Why?
|
| Heart Transplantation | 1 | 2020 | 1 | 0.050 |
Why?
|
| Defibrillators, Implantable | 1 | 2020 | 1 | 0.050 |
Why?
|
| Heart-Assist Devices | 1 | 2020 | 2 | 0.050 |
Why?
|
| Pacemaker, Artificial | 1 | 2020 | 2 | 0.050 |
Why?
|
| Acute Disease | 1 | 2020 | 105 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 41 | 0.040 |
Why?
|
| Fibrosis | 1 | 2019 | 11 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 243 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2019 | 939 | 0.030 |
Why?
|
| Reoperation | 1 | 2014 | 8 | 0.030 |
Why?
|
| Prosthesis Design | 1 | 2014 | 11 | 0.030 |
Why?
|
| Equipment Design | 1 | 2014 | 27 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 1377 | 0.030 |
Why?
|
| Child | 1 | 2019 | 2180 | 0.030 |
Why?
|
| Adolescent | 1 | 2019 | 2858 | 0.030 |
Why?
|